**Makers of Humira and Enbrel Using New Patents to Delay Generic Versions**

July 2016

The companies behind best-selling drugs Humira and Enbrel, used to treat rheumatoid arthritis, psoriasis and other autoimmune diseases, and which cost around $50,000 a year, are deploying new patents to prevent patients and insurers from getting two essentially generic versions of the drugs for less money.

<https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html?_r=0>